Imported medicines and an established pharmacy business

Georgia buys pharmaceutical products from international manufacturers and distributes them through pharmacies, wholesalers and healthcare institutions. The supplier's customer can therefore be a chain's buying organisation, a wholesale distributor or a hospital purchasing a particular product. These businesses overlap, but each performs a different part of the journey from factory to patient.

The country also has pharmaceutical manufacturing. It ranges from conventional formulations to specialised biological products. Manufacturing, import distribution and retail should consequently appear separately in an account of the industry. A local factory's exports and a distributor's re-exports both enter trade records, but describe different commercial activity. Geostat's external-trade system allows analysis by commodity, partner and period, with those definitions retained. [1]

Aversi and the Aversi-Rational factory

Aversi's business began in 1994 and developed beyond a pharmacy network into related healthcare activities. Its own company history identifies pharmacies, Aversi-Rational manufacturing, Aversi clinics and the Alpha insurance business. The brand therefore appears at several points in the healthcare economy rather than solely as a shopfront. [2]

Aversi-Rational was established in the early 2000 s and introduced its first medicine in 2005, according to the group's history. It manufactures pharmaceutical products and supplies export markets as well as Georgia. This is a different business from importing a finished branded medicine: production involves manufacturing premises, equipment, materials, quality systems and batch responsibility.

The same example helps explain the commercial appeal of related activities in Georgia. A pharmacy network brings frequent customer contact and product distribution, while clinics generate demand for healthcare services and supplies. Manufacturing adds a further industrial activity with its own investment and regulatory requirements. The activities can sit within one brand family while still requiring separate operational and contractual treatment.

GPC, Pharmadepot and the wholesale channel

GEPHA describes a dual-brand pharmacy business: GPC addresses a higher-income segment and Pharmadepot a mass-market segment. It combines these retail operations with wholesale supply. The company describes its pharmacies as present in Tbilisi and other major regional cities. [3] A foreign supplier approaching this part of the market is dealing with an established buyer and distribution organisation, rather than merely negotiating with individual branches.

The two banners also demonstrate how pharmacy retail includes more than prescription medicines. Personal care, baby products and other non-medication categories form part of the customer offer. Brand positioning affects store format, assortment and customer service. A premium skincare line and a routinely purchased medicine may reach the same building through different buying decisions and promotional arrangements.

GEPHA has also introduced websites and applications for GPC and Pharmadepot, with online ordering and collection-related functions. Its published digital services connect the existing pharmacy network with another customer interface. [4] This creates commercial work in product descriptions, catalogue information and order fulfilment alongside the established wholesale and branch-delivery operations.

PSP and health-and-beauty retail

PSP is another recognisable participant in Georgian pharmacy retail. Its public online shop separates medicines, cosmetics and mother-and-baby products. [5] The category mix illustrates a local distribution feature already visible in the older Georgian market: pharmaceutical networks are also important points of sale for imported personal-care products.

For a manufacturer, that matters to the choice of commercial partner. A product may be sold through a specialist perfumery chain, an ordinary supermarket or a pharmacy depending on its identity and intended customer. The pharmacy setting does not turn every product into a medicine. It does provide a retail environment where health, personal care and recurring purchases share a customer relationship.

BioChimPharm and Georgia’s bacteriophage tradition

BioChimPharm represents a specialised part of Georgian pharmaceutical production. The company operates research and manufacturing facilities in Tbilisi and develops bacteriophage-based products. Its published history connects the business to the country's longstanding bacteriophage work. In 2023 it announced the modernisation of its historical manufacturing premises and work on GMP compliance. [6]

This is an example of an industrial and research capability with a particular Georgian background. It can be discussed as a manufacturing and commercialisation business without making a medical claim about a product's suitability for an individual. The commercial subjects include product authorisation, manufacturing rights, scientific information, distribution and the requirements of each destination market.

The example also places the Georgian sector in perspective. A country can have specialised local production and a large imported assortment at the same time. The relevant comparison for a supplier is the particular product category and channel, rather than an assumption that local manufacturing either supplies every need or has disappeared entirely.

Product admission, pharmacy categories and reference prices

The Medicines and Pharmaceutical Activities Law provides recognition and national systems for granting marketing authorisation. It also distinguishes products under special control, prescription medicines and non-prescription products. Retail permissions and dispensing rules depend on the product group and outlet type. Manufacturing is subject to its own permit arrangements. [7]

The law provides for a public reference-price catalogue and prohibits the relevant wholesale or retail sales above the applicable reference prices, with the statutory exceptions for import, export and re-export transactions. Commercial pricing therefore involves both supplier terms and the regulatory treatment of the medicine. The price at which an imported batch was purchased does not by itself establish the price at which every later sale may be made.

These rules also affect promotion. The law restricts advertising by product group, so a general consumer-products advertising campaign cannot simply be applied to a prescription-medicine portfolio. The company's marketing, sales and regulatory functions meet at product information, packaging, claims and the channel through which the product is supplied.

Commercial participation in the sector

The established market supports several forms of participation: supplying a chain, using a wholesaler, manufacturing locally, providing equipment and materials to factories, or selling supporting services to pharmacies and hospitals. Inventory, shelf life and delivery reliability are central commercial subjects because medicines and associated products pass through a continuing replenishment system. The Georgian agreement determines who owns stock, bears credit exposure and handles returns or product complaints.

MarketEntry.ge assists pharmaceutical and health-product businesses with market research, commercial introductions and legal coordination in Georgia. Related articles cover healthcare institutions and cosmetics and perfumery distribution. Contact us to discuss a defined product portfolio or manufacturing project.